APA (7th ed.) Citation

Zhang, Q., Wu, P., He, X., Ding, Y., & Shu, Y. (2021). Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China. Frontiers Media S.A.

Chicago Style (17th ed.) Citation

Zhang, Qilin, Pan Wu, Xucheng He, Yufeng Ding, and Yamin Shu. Cost-Effectiveness Analysis of Camrelizumab Vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China. Frontiers Media S.A, 2021.

MLA (8th ed.) Citation

Zhang, Qilin, et al. Cost-Effectiveness Analysis of Camrelizumab Vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China. Frontiers Media S.A, 2021.